John L. Higgins - Nov 1, 2022 Form 4/A - Amendment Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Reardon, Attorney-in-Fact for John L. Higgins
Stock symbol
LGND
Transactions as of
Nov 1, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
11/7/2022, 07:29 PM
Date Of Original Report
Nov 3, 2022
Previous filing
Oct 31, 2022
Next filing
Nov 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LGND Common Stock 427K Nov 1, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Form 4 filed on November 3, 2022 inadvertently understated the amount of shares beneficially held in column 5 by 2,000 shares. The number reported herein is correct.